Aurobindo Pharma Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Aurobindo Pharma de 16.9% y 8.7% por año respectivamente. Se prevé que el BPA crezca en un 17.5% al año. Se espera que la rentabilidad financiera sea de 11.3% en 3 años.

Información clave

13.4%

Tasa de crecimiento de los beneficios

13.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	17.0%
Tasa de crecimiento de los ingresos	7.5%
Rentabilidad financiera futura	11.4%
Cobertura de analistas	Good
Última actualización	03 Jun 2024

Actualizaciones recientes sobre el crecimiento futuro

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

May 29

Recent updates

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

May 29

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

May 22

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Apr 10

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Jan 14

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Dec 27

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 07

Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Jun 14

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

May 21

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Feb 11

Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Jan 09

Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

Nov 02

These 4 Measures Indicate That Aurobindo Pharma (NSE:AUROPHARMA) Is Using Debt Reasonably Well

Nov 27

Aurobindo Pharma's (NSE:AUROPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Nov 10

Previsiones de crecimiento de beneficios e ingresos

NSEI:AUROPHARMA - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2027	357,601	45,370	41,572	59,658	11
3/31/2026	346,192	45,278	38,377	54,174	25
3/31/2025	316,598	39,082	29,843	47,773	25
3/31/2024	290,019	31,730	-11,270	24,345	N/A
12/31/2023	278,947	27,705	N/A	N/A	N/A
9/30/2023	269,500	23,254	-16,080	19,946	N/A
6/30/2023	254,700	19,777	N/A	N/A	N/A
3/31/2023	248,554	19,275	-3,336	23,868	N/A
12/31/2022	241,918	19,977	N/A	N/A	N/A
9/30/2022	237,869	21,112	28,497	52,208	N/A
6/30/2022	239,894	23,987	N/A	N/A	N/A
3/31/2022	234,555	26,482	23,118	50,165	N/A
12/31/2021	236,476	28,676	N/A	N/A	N/A
9/30/2021	240,103	52,109	1,278	28,769	N/A
6/30/2021	245,518	53,217	N/A	N/A	N/A
3/31/2021	247,746	53,348	14,552	33,291	N/A
12/31/2020	249,316	53,831	N/A	N/A	N/A
9/30/2020	244,617	31,421	29,266	42,542	N/A
6/30/2020	235,787	29,757	N/A	N/A	N/A
3/31/2020	230,985	28,451	29,502	43,813	N/A
12/31/2019	222,323	25,666	N/A	N/A	N/A
9/30/2019	216,070	25,733	N/A	N/A	N/A
6/30/2019	207,579	25,449	N/A	N/A	N/A
3/31/2019	195,636	23,647	919	16,510	N/A
12/31/2018	183,834	23,078	N/A	N/A	N/A
9/30/2018	174,246	21,906	N/A	N/A	N/A
6/30/2018	171,091	23,603	N/A	N/A	N/A
3/31/2018	164,630	24,232	4,246	19,545	N/A
12/31/2017	159,381	24,271	N/A	N/A	N/A
9/30/2017	154,903	24,107	N/A	N/A	N/A
6/30/2017	148,279	22,352	N/A	N/A	N/A
3/31/2017	149,334	23,017	N/A	32,786	N/A
12/31/2016	151,565	22,809	N/A	N/A	N/A
9/30/2016	147,559	22,466	N/A	N/A	N/A
6/30/2016	143,446	20,945	N/A	N/A	N/A
3/31/2016	138,162	20,251	N/A	14,198	N/A
12/31/2015	133,249	18,230	N/A	N/A	N/A
9/30/2015	129,956	16,724	N/A	N/A	N/A
6/30/2015	125,433	15,928	N/A	N/A	N/A
3/31/2015	121,340	15,758	N/A	12,368	N/A
12/31/2014	112,825	16,738	N/A	N/A	N/A
9/30/2014	102,756	17,069	N/A	N/A	N/A
6/30/2014	93,109	15,697	N/A	N/A	N/A
3/31/2014	81,002	11,729	N/A	6,463	N/A
12/31/2013	73,736	7,797	N/A	N/A	N/A
9/30/2013	67,900	4,540	N/A	N/A	N/A
6/30/2013	63,736	4,414	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (16.9% al año) de AUROPHARMA es superior a la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Se prevé que los beneficios (13.5% al año) de AUROPHARMA crezcan menos que el mercado Indian (16% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de AUROPHARMA crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (8.7% al año) de AUROPHARMA crezcan más despacio que el mercado de Indian (10.2% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 8.7% al año) de AUROPHARMA crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de AUROPHARMA sea baja dentro de 3 años (11.3%).

Aurobindo Pharma Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 7.9% to ₹1,292

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

Price target increased by 7.6% to ₹1,087

Price target increased by 7.5% to ₹1,085

Price target increased by 7.2% to ₹1,071

Price target increased by 10% to ₹956

Recent updates

Price target increased by 7.9% to ₹1,292

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Now 21% overvalued after recent price rise

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Aurobindo Pharma Limited Announces Retirement of K. Ragunathan as Chairman of Board of Directors, Effective March 31, 2024

Aurobindo Pharma Limited Appoints N. Ravikiran as Chief Business Officer

Insider recently sold ₹2.1m worth of stock

Less than half of directors are independent

Dividend reduced to ₹1.50

Aurobindo Pharma Limited Receives USFDA Approval for Deflazacort Tablets, 6 mg, 18 mg, 30 mg, and 36 mg

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Aurobindo Pharma Limited Approves the Resignation of Dr.(Mrs.) Avnit Bimal Singh as an Independent Director

Price target increased by 7.6% to ₹1,087

Price target increased by 7.5% to ₹1,085

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Price target increased by 7.2% to ₹1,071

Insider recently sold ₹9.7m worth of stock

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Insider recently sold ₹1.6m worth of stock

New minor risk - Insider selling

Price target increased by 10% to ₹956

Upcoming dividend of ₹3.00 per share at 0.3% yield

Aurobindo Pharma Limited Approves First Interim Dividend, Payable on or Before December 4, 2023

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Associate President of RAD- II recently sold ₹1.6m worth of stock

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Aurobindo Pharma Limited Announces Interim Dividend for the Financial Year 2022-23

Price target increased by 8.2% to ₹721

Aurobindo Pharma Limited Announces Resignation of M. Sivakumaran as Whole-Time Director and Director

Full year 2023 earnings: EPS misses analyst expectations

Aurobindo Pharma Limited to Report Q2, 2024 Results on Nov 14, 2023

Aurobindo Pharma Limited Receives USFDA Approval for Saxagliptin Tablets, 2.5 Mg and 5 Mg

Aurobindo Pharma Limited, Annual General Meeting, Aug 25, 2023

Aurobindo Pharma Limited Announces Completion of US Fda Inspection At Unit III At Bachupally Village, Medchal Malkajgiri District, Telangana

Aurobindo Pharma Limited Announces Classification of US FDA Inspection At Unit XIV, Anakapalli District, Andhra Pradesh

Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Price target increased by 9.0% to ₹643

Full year 2023 earnings: EPS misses analyst expectations

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

Insider recently sold ₹1.3m worth of stock

Insider recently bought ₹3.2m worth of stock

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Aurobindo Pharma Limited Approves First Interim Dividend, Payable on or Before March 3, 2023

Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Aurobindo Pharma Limited Announces Completion Of US FDA Inspection At Unit IX - Reg

Consensus EPS estimates fall by 15%

Price target decreased to ₹621

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

Insider recently sold ₹11m worth of stock

Insider recently sold ₹2.7m worth of stock

Aurobindo Pharma Limited (NSEI:AUROPHARMA) completed the acquisition of 34% stake in GLS Pharma Ltd from Suresh and Sunita Pathak.

Full year 2022 earnings: EPS and revenues miss analyst expectations

Aurobindo Pharma Limited to Report Q4, 2023 Results on May 30, 2023

Aurobindo Pharma Limited, Annual General Meeting, Aug 02, 2022

Aurobindo Pharma Limited, Annual General Meeting, Aug 02, 2022

We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

Teva Branded Pharmaceutical Products R&D, Inc. and Auspex Pharmaceuticals, Inc. Announces Settlement with Aurobindo to Resolve AUSTEDO® (deutetrabenazine) Patent Dispute

Consensus EPS estimates fall by 11%

Price target decreased to ₹734

Aurobindo Pharma Limited Announces Fourth Interim Dividend for the Financial Year 2021-22, Payable on or Before June 15, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)